• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

临床试验和基因组研究中的多重假设检验程序。

Multiple hypotheses testing procedures in clinical trials and genomic studies.

机构信息

Department of Statistics, The George Washington University , Washington, DC , USA.

出版信息

Front Public Health. 2013 Dec 9;1:63. doi: 10.3389/fpubh.2013.00063. eCollection 2013.

DOI:10.3389/fpubh.2013.00063
PMID:24350232
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3859974/
Abstract

We review and compare multiple hypothesis testing procedures used in clinical trials and those in genomic studies. Clinical trials often employ global tests, which draw an overall conclusion for all the hypotheses, such as SUM test, Two-Step test, Approximate Likelihood Ratio test (ALRT), Intersection-Union Test (IUT), and MAX test. The SUM and Two-Step tests are most powerful under homogeneous treatment effects, while the ALRT and MAX test are robust in cases with non-homogeneous treatment effects. Furthermore, the ALRT is robust to unequal sample sizes in testing different hypotheses. In genomic studies, stepwise procedures are used to draw marker-specific conclusions and control family wise error rate (FWER) or false discovery rate (FDR). FDR refers to the percent of false positives among all significant results and is preferred over FWER in screening high-dimensional genomic markers due to its interpretability. In cases where correlations between test statistics cannot be ignored, Westfall-Young resampling method generates the joint distribution of P-values under the null and maintains their correlation structure. Finally, the GWAS data from a clinical trial searching for SNPs associated with nephropathy among Type 1 diabetic patients are used to illustrate various procedures.

摘要

我们回顾和比较了临床试验和基因组研究中使用的多种假设检验程序。临床试验通常采用全局检验,对所有假设进行总体结论,如 SUM 检验、两步检验、近似似然比检验(ALRT)、交集并集检验(IUT)和 MAX 检验。SUM 和两步检验在同质处理效应下最有效,而 ALRT 和 MAX 检验在处理效应非同质的情况下具有稳健性。此外,ALRT 在检验不同假设时对不等样本量具有稳健性。在基因组研究中,逐步程序用于得出标记特异性结论,并控制家族错误率(FWER)或假发现率(FDR)。FDR 是指所有显著结果中假阳性的百分比,由于其可解释性,在筛选高维基因组标记时优于 FWER。在不能忽略检验统计量之间相关性的情况下,Westfall-Young 重抽样方法生成零假设下 P 值的联合分布,并保持它们的相关结构。最后,使用来自临床试验的 GWAS 数据,该试验旨在寻找与 1 型糖尿病患者肾病相关的 SNPs,来说明各种程序。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d5d/3859974/7cd356f1bab6/fpubh-01-00063-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d5d/3859974/7cd356f1bab6/fpubh-01-00063-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d5d/3859974/7cd356f1bab6/fpubh-01-00063-g001.jpg

相似文献

1
Multiple hypotheses testing procedures in clinical trials and genomic studies.临床试验和基因组研究中的多重假设检验程序。
Front Public Health. 2013 Dec 9;1:63. doi: 10.3389/fpubh.2013.00063. eCollection 2013.
2
POWER-ENHANCED MULTIPLE DECISION FUNCTIONS CONTROLLING FAMILY-WISE ERROR AND FALSE DISCOVERY RATES.控制家族性错误率和错误发现率的功率增强型多重决策函数
Ann Stat. 2011 Feb;39(1):556-583. doi: 10.1214/10-aos844.
3
Resampling-based stepwise multiple testing procedures with applications to clinical trial data.基于重采样的逐步多重检验程序及其在临床试验数据中的应用。
Pharm Stat. 2021 Mar;20(2):297-313. doi: 10.1002/pst.2076. Epub 2020 Oct 25.
4
Multiple testing. Part I. Single-step procedures for control of general type I error rates.多重检验。第一部分。控制一般I型错误率的单步程序。
Stat Appl Genet Mol Biol. 2004;3:Article13. doi: 10.2202/1544-6115.1040. Epub 2004 Jun 9.
5
SOME STEP-DOWN PROCEDURES CONTROLLING THE FALSE DISCOVERY RATE UNDER DEPENDENCE.一些在相依性下控制错误发现率的逐步降阶程序。
Stat Sin. 2008;18(3):881-904.
6
A multiple-testing procedure for high-dimensional mediation hypotheses.一种用于高维中介假设的多重检验程序。
J Am Stat Assoc. 2022;117(537):198-213. doi: 10.1080/01621459.2020.1765785. Epub 2020 Jun 24.
7
Control procedures and estimators of the false discovery rate and their application in low-dimensional settings: an empirical investigation.控制程序和虚假发现率的估计及其在低维环境中的应用:实证研究。
BMC Bioinformatics. 2018 Mar 2;19(1):78. doi: 10.1186/s12859-018-2081-x.
8
Augmentation procedures for control of the generalized family-wise error rate and tail probabilities for the proportion of false positives.用于控制广义族错误率和假阳性比例的尾概率的增强程序。
Stat Appl Genet Mol Biol. 2004;3:Article15. doi: 10.2202/1544-6115.1042. Epub 2004 Jun 15.
9
Resampling-based empirical Bayes multiple testing procedures for controlling generalized tail probability and expected value error rates: focus on the false discovery rate and simulation study.基于重采样的经验贝叶斯多重检验程序,用于控制广义尾概率和期望值错误率:聚焦于错误发现率及模拟研究
Biom J. 2008 Oct;50(5):716-44. doi: 10.1002/bimj.200710473.
10
Controlling the false discovery rate with constraints: the Newman-Keuls test revisited.带约束条件控制错误发现率:重新审视纽曼-基尔斯检验。
Biom J. 2007 Feb;49(1):136-43. doi: 10.1002/bimj.200610297.

引用本文的文献

1
Effect of COVID-19 Vaccine Messaging Platforms in Emergency Departments on Vaccine Acceptance and Uptake: A Cluster Randomized Clinical Trial.**译文**: 急诊科新冠疫苗信息平台对疫苗接受度和接种率的影响:一项集群随机临床试验。
JAMA Intern Med. 2023 Feb 1;183(2):115-123. doi: 10.1001/jamainternmed.2022.5909.
2
Applications of the Wei-Lachin multivariate one-sided test for multiple outcomes on possibly different scales.Wei-Lachin多变量单侧检验在可能具有不同尺度的多个结果上的应用。
PLoS One. 2014 Oct 17;9(10):e108784. doi: 10.1371/journal.pone.0108784. eCollection 2014.
3
Gastric cancer drug trials - are women second class citizens?

本文引用的文献

1
Multivariate one-sided multiple comparison procedure with a control based on the approximate likelihood ratio test.
Biom J. 2010 Dec;52(6):771-83. doi: 10.1002/bimj.200900203.
2
Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study.多种超氧化物歧化酶1/剪接因子丝氨酸丙氨酸15变体与糖尿病肾病的发生和进展相关:糖尿病控制与并发症试验/糖尿病干预与并发症遗传学研究
Diabetes. 2008 Jan;57(1):218-28. doi: 10.2337/db07-1059. Epub 2007 Oct 3.
3
A note on one-sided tests with multiple endpoints.关于具有多个终点的单侧检验的一则注释。
胃癌药物试验——女性是二等公民吗?
Nat Rev Clin Oncol. 2014 Jul;11(7). doi: 10.1038/nrclinonc.2013.231-c2. Epub 2014 Jun 3.
Biometrics. 2004 Mar;60(1):276-9; discussion 279-80. doi: 10.1111/j.0006-341X.2004.00159.x.
4
Statistical significance for genomewide studies.全基因组研究的统计学显著性
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5. doi: 10.1073/pnas.1530509100. Epub 2003 Jul 25.
5
One-sided tests in clinical trials with multiple endpoints.具有多个终点的临床试验中的单侧检验。
Biometrics. 2001 Dec;57(4):1039-47. doi: 10.1111/j.0006-341x.2001.01039.x.
6
On the design and analysis of randomized clinical trials with multiple endpoints.关于具有多个终点的随机临床试验的设计与分析
Biometrics. 1993 Mar;49(1):23-30.
7
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.糖尿病强化治疗对胰岛素依赖型糖尿病长期并发症发生及进展的影响。
N Engl J Med. 1993 Sep 30;329(14):977-86. doi: 10.1056/NEJM199309303291401.
8
Statistical methods in cancer research. Volume I - The analysis of case-control studies.癌症研究中的统计方法。第一卷——病例对照研究的分析
IARC Sci Publ. 1980(32):5-338.
9
Procedures for comparing samples with multiple endpoints.用于比较具有多个终点的样本的程序。
Biometrics. 1984 Dec;40(4):1079-87.
10
The analysis of multiple endpoints in clinical trials.临床试验中多个终点的分析
Biometrics. 1987 Sep;43(3):487-98.